AKERO THERAPEUTICS IN

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

15 11 2024 11:00:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

13 11 2024 16:05:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

08 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

21 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

30 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

09 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

28 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

09 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

11 6 2024 07:00:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

08 6 2024 08:15:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

29 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

10 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

08 5 2024 07:00:01 提供 Nasdaq GlobeNewswire

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

30 4 2024 08:00:01 提供 Nasdaq GlobeNewswire

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

08 3 2024 16:02:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

07 3 2024 16:01:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

05 3 2024 21:13:56 提供 Nasdaq GlobeNewswire

Akero Therapeutics Announces Proposed Public Offering of Common Stock

04 3 2024 16:21:12 提供 Nasdaq GlobeNewswire

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

04 3 2024 06:00:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH

29 2 2024 08:00:00 提供 Nasdaq GlobeNewswire